Would immunization be the same without cross-reactivity?

This video supports the published article Vojtek I, Buchy P, Doherty TM, Hoet B.Would immunization be the same without cross-reactivity? Vaccine. 2019;37(4):539-549. doi: 10.1016/j.vaccine.2018.12.005. In this article, we review the concepts of ‘cross-reactivity’ and ‘cross-protection’ which are both common and important from a public health perspective. Real-world cross-protection data are now available for several vaccines (e.g. those against diseases caused by human papillomavirus and rotavirus). Through this article, we reviewed the growing body of evidence to highlight the full impact of vaccines – beyond vaccine-type disease – that should be taken into consideration when assessing the full value of vaccination programs. With the advent of the next generation of vaccine technologies, we think cross-reactivity might become the solution to creating vaccines against highly antigenically and genetically diverse pathogens.

本视频对应已发表学术论文：Vojtek I、Buchy P、Doherty TM、Hoet B. 若无交叉反应性，免疫接种是否仍具意义？[J]. Vaccine, 2019, 37(4):539-549. DOI: 10.1016/j.vaccine.2018.12.005. 本文对交叉反应性（cross-reactivity）与交叉保护（cross-protection）的核心概念展开综述，二者从公共卫生视角而言均兼具普遍性与重要性。目前已有多项疫苗的真实世界交叉保护数据公开发布，例如针对人乳头瘤病毒（human papillomavirus）与轮状病毒（rotavirus）所致疾病的疫苗。本文梳理了日益增长的相关证据体系，旨在凸显疫苗的完整效应边界：即超越疫苗对应型别疾病的保护作用，这一维度在评估疫苗接种项目的整体价值时理应被纳入考量范畴。随着新一代疫苗技术的涌现，我们认为交叉反应性有望成为研发针对抗原性与遗传多样性极高的病原体的疫苗的关键解决方案。